Group 1 - Shanghai is actively promoting high-level opening-up and placing greater emphasis on technological innovation as part of its 14th Five-Year Plan, aiming to create a stable and transparent development environment for global enterprises [2] - The biopharmaceutical sector is one of the three key industries prioritized for development in Shanghai, with Boehringer Ingelheim being a leading global biopharmaceutical company encouraged to enhance its innovation and R&D efforts in the region [2] - Zeiss, a global leader in optical and optoelectronic manufacturing, is welcomed to leverage its brand and professional advantages to enhance its regional headquarters' functions and contribute to a more competitive industrial ecosystem [2] Group 2 - Boehringer Ingelheim's commitment to increasing innovation investments in Shanghai aims to deepen collaboration in drug development and better serve global patients [3] - Zeiss expresses confidence in investing in Shanghai, citing the city's dynamic development and efficient business environment as key factors for its strategic decisions [3] - Both companies are encouraged to participate in building an open innovation ecosystem and to push for breakthroughs in technology and industry innovation [3]
为全球企业在沪深耕发展提供新机遇拓展合作空间
Xin Lang Cai Jing·2026-02-09 07:58